16 aug, 2016 - Grif_ls is proud to support the Canadian Blood Services' Missing Type Campaign. This is a global campaign whose goal is to increase the number of new registered blood donors. In the last decade there has been a downward trend of new registered blood donors, which may put the blood supply at risk
01 aug, 2016 - The conclusions of the trial were presented at the Alzheimer's Association International Conference in Toronto. The compound ABvac40, designed to combat Alzheimer's disease at its initial stage, has demonstrated a good safety and tolerability profile.
22 jul, 2016 - The plot is located in the Spanish town of Lliçà de Vall, a future industrial park adjacent to the industrial park of Llevant of Parets del Vallès, where currently Grifols has production facilities
05 jul, 2016 - GammaSTAN®, Gamunex® / Gamunex-C®, HyperHEP B®, HyperRAB®, HyperRHO®, HyperTET®, Koāte® DVI, Plasbumin®, Prolastin® / Prolastin® C and Thrombate® III are the newly added products
29 feb, 2016 - Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) reported net revenues of Euros 3,934.6 million for 2015, growing +17.3% compared to Euros 3,355.4 million reported in 2014. Exchange rates movements, in particular of the US Dollar, had a positive impact on revenues; that grew +2.5% at constant currency (cc).
26 jan, 2016 - AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the "natural killer" cells responsible for destroying cells infected by the virus
08 jan, 2016 - Almost all cases of tetanus in the U.S. occur in people who have never been immunized or who have not had a tetanus booster shot within the preceding 10 years